Skip to main content

Pancreatic Cancer Clinical Trials

Review the pancreatic cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 302

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
Status: Active
Location: 341 locations
Testing the Use of the Usual Chemotherapy before and after Surgery for Removable Pancreatic Cancer
Status: Active
Location: 340 locations
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Status: Active
Location: 390 locations
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Status: Active
Location: 108 locations
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active
Location: 33 locations
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients with Locally Advanced Pancreatic Cancer
Status: Active
Location: 35 locations
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
Status: Active
Location: 24 locations
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
Status: Active
Location: 26 locations
A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
Status: Active
Location: 23 locations
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Status: Active
Location: 21 locations
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Status: Active
Location: 20 locations
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Status: Active
Location: 20 locations
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Status: Active
Location: 17 locations
A Study of ASP3082 in Adults With Advanced Solid Tumors
Status: Active
Location: 17 locations
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Status: Active
Location: 17 locations
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Status: Active
Location: 16 locations
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
Status: Active
Location: 15 locations
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Status: Active
Location: 13 locations
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Status: Active
Location: 12 locations
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Status: Active
Location: 10 locations
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Status: Active
Location: 10 locations
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib during Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
Status: Active
Location: 10 locations
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Status: Active
Location: 11 locations
A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Participants with Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Status: Active
Location: 9 locations
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Status: Active
Location: 9 locations